Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mayumi Niimura"'
Autor:
Chanida Thinyakul, Yasuhisa Sakamoto, Mayuko Shimoda, Yanliang Liu, Suyanee Thongchot, Omnia Reda, Akihiro Nita, Romgase Sakamula, Somponnat Sampattavanich, Ayato Maeda, Paweenapon Chunthaboon, David Nduru, Mayumi Niimura, Yohei Kanamori, Peti Thuwajit, Keiichi I. Nakayama, Kun-Liang Guan, Yorifumi Satou, Chanitra Thuwajit, Toshiro Moroishi
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-15 (2024)
Abstract Cancer cells adeptly manipulate the tumor microenvironment (TME) to evade host antitumor immunity. However, the role of cancer cell-intrinsic signaling in shaping the immunosuppressive TME remains unclear. Here, we found that the Hippo pathw
Externí odkaz:
https://doaj.org/article/78c73de30af2440f83df06f6fbe4a097
Autor:
Taishi Yamane, Yohei Kanamori, Hiroshi Sawayama, Hiromu Yano, Akihiro Nita, Yudai Ohta, Hironori Hinokuma, Ayato Maeda, Akiko Iwai, Takashi Matsumoto, Mayuko Shimoda, Mayumi Niimura, Shingo Usuki, Noriko Yasuda-Yoshihara, Masato Niwa, Yoshifumi Baba, Takatsugu Ishimoto, Yoshihiro Komohara, Tomohiro Sawa, Tasuku Hirayama, Hideo Baba, Toshiro Moroishi
Publikováno v:
JCI Insight, Vol 7, Iss 21 (2022)
Accumulating evidence suggests that high levels of Fusobacterium nucleatum in colorectal tumor tissues can be associated with poor prognosis in patients with colorectal cancer (CRC); however, data regarding distinct prognostic subgroups in F. nucleat
Externí odkaz:
https://doaj.org/article/c71c3d7d698a4943bc0c2d530da4aca7
Autor:
Howard B. Cottam, Masaharu Yuki, Masahiro Wakao, Dennis A. Carson, Mayumi Niimura, Takayoshi Yamauchi, Tomoko Hayashi, Toshiro Moroishi, Yasuo Suda, Hiroyuki Shinchi
Publikováno v:
ACS Applied Bio Materials. 4:2732-2741
Toll-like receptors (TLRs) are pattern recognition receptors that activate innate immunity, and their ligands are promising adjuvants for vaccines and immunotherapies. Small molecule TLR7 ligands are ideal vaccine adjuvants as they induce not only pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::225f9403e90b1009681b58cf5f4a49ce
https://doi.org/10.1021/acsabm.0c01639
https://doi.org/10.1021/acsabm.0c01639
Autor:
TAKASHI KARASHIMA1, MAYUMI NIIMURA1, HIROTO OSAKABE1, TSUTOMU SHIMAMOTO1, SATOSHI FUKATA1, KEIJI INOUE1, TARO SHUIN1, KEIKO UDAKA2, KATSUHIDE SUZUKI2, NAOTO KURODA3, MOTOHARU SEIKI4
Publikováno v:
Oncology Letters. Jul2017, Vol. 14 Issue 1, p1162-1166. 5p. 1 Chart, 2 Graphs.
Autor:
Toshihiro Komatsu, Naoto Kuroda, Keiko Udaka, Mayumi Niimura, Masayuki Kamada, Takashi Karashima, Taro Shuin, Chiaki Kawada, Keiji Inoue
Publikováno v:
International Journal of Urology. 21:702-706
Objectives To investigate whether the combination of the imidazoquinoline immune response modifier, imiquimod, and the multitargeted tyrosine-kinase inhibitor, sorafenib, inhibits the growth of renal cell carcinoma in mice. Methods Female BALB/c mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0bc44d3d88d126d299439b170c54741
https://doi.org/10.1111/iju.12401
https://doi.org/10.1111/iju.12401
Autor:
Mayumi Niimura, Keiji Inoue, Tsutomu Shimamoto, Katsuhide Suzuki, Keiko Udaka, Motoharu Seiki, Naoto Kuroda, Takashi Karashima, Hiroto Osakabe, Taro Shuin, Satoshi Fukata
Publikováno v:
Oncology letters. 14(1)
Imiquimod is an imidazoquinoline immune response modifier that is used in antiviral and antiallergic creams. Combination therapy using transcutaneous imiquimod and oral sorafenib was previously demonstrated to reduce the tumor burden of renal cell ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03dc917ecbad0269f1d7b0d52f92eff3
https://pubmed.ncbi.nlm.nih.gov/28693290
https://pubmed.ncbi.nlm.nih.gov/28693290
Autor:
Takashi, Karashima, Toshihiro, Komatsu, Mayumi, Niimura, Chiaki, Kawada, Masayuki, Kamada, Keiji, Inoue, Keiko, Udaka, Naoto, Kuroda, Taro, Shuin
Publikováno v:
International journal of urology : official journal of the Japanese Urological Association. 21(7)
To investigate whether the combination of the imidazoquinoline immune response modifier, imiquimod, and the multitargeted tyrosine-kinase inhibitor, sorafenib, inhibits the growth of renal cell carcinoma in mice.Female BALB/c mice were implanted subc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7ed9c969fe9894c2d3c8d0f14196be82
https://pubmed.ncbi.nlm.nih.gov/24571181
https://pubmed.ncbi.nlm.nih.gov/24571181